Silent Killer in the Brain: How Maple Syrup Urine Disease Deceives Doctors and Threatens Adult Patients

Maple syrup urine disease (MSUD) represents one of medicine's most deceptive challenges, a rare inherited metabolic disorder where patients can appear dangerously well while their brains swell dangerously. As reported…

Continue Reading Silent Killer in the Brain: How Maple Syrup Urine Disease Deceives Doctors and Threatens Adult Patients

The Zebra and the Bear: How a Mother’s Fierce Determination to Save Her Daughter May Lead to a Promising Gene Therapy Clinical Trial

I was introduced to Amber Olsen, the “mama bear” in my new documentary film, The Zebra and the Bear, in the spring of 2016. A mutual friend asked if I…

Continue Reading The Zebra and the Bear: How a Mother’s Fierce Determination to Save Her Daughter May Lead to a Promising Gene Therapy Clinical Trial

Second Chance at Life: Glofitamab Accelerates Hope for Aggressive Blood Cancer Patients on NHS

The NHS has dramatically expanded access to a life-saving cancer therapy, according to NHS England, offering approximately 300 blood cancer patients in England annually a genuine chance at complete remission.…

Continue Reading Second Chance at Life: Glofitamab Accelerates Hope for Aggressive Blood Cancer Patients on NHS

Gene Therapy Revolution: Waskyra Offers Life-Changing Hope for Wiskott-Aldrich Syndrome Patients

A groundbreaking achievement in genetic medicine has emerged as the European Medicines Agency (EMA) recommended approval of Waskyra (etuvetidigene autotemcel), the first gene therapy specifically designed to treat Wiskott-Aldrich syndrome…

Continue Reading Gene Therapy Revolution: Waskyra Offers Life-Changing Hope for Wiskott-Aldrich Syndrome Patients

FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

Hypereosinophilic syndrome (HES) patients may finally have a meaningful treatment option. According to an article published at BusinessWire.com, AstraZeneca's FASENRA (benralizumab) has shown statistically significant efficacy in delaying disease progression,…

Continue Reading FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

Tonix Advances Novel Oxytocin Treatment for Prader-Willi Syndrome into Clinical Testing

Tonix Pharmaceuticals announced plans to initiate Phase 2 clinical trials in 2026 for TNX-2900, an innovative intranasal oxytocin formulation designed to treat Prader-Willi Syndrome (PWS), a rare genetic disorder characterized…

Continue Reading Tonix Advances Novel Oxytocin Treatment for Prader-Willi Syndrome into Clinical Testing

Mezagitamab Demonstrates Lasting Kidney Protection 18 Months After Final Dose in IgA Nephropathy

Takeda Pharmaceutical Company announced promising interim data from a Phase 1b clinical trial demonstrating that mezagitamab (TAK-079), an experimental immunotherapy, maintains kidney function stability for extended periods even after treatment…

Continue Reading Mezagitamab Demonstrates Lasting Kidney Protection 18 Months After Final Dose in IgA Nephropathy

FDA Rejects Rare Disease Treatment Despite Strong Clinical Data: Biohaven Challenges Regulatory Decision on Spinocerebellar Ataxia Drug

Biohaven Pharmaceuticals faced a significant setback when the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for Vyglxia (troriluzole), a promising…

Continue Reading FDA Rejects Rare Disease Treatment Despite Strong Clinical Data: Biohaven Challenges Regulatory Decision on Spinocerebellar Ataxia Drug

Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 2

Please go HERE to read Part 1 of this article The company, GEMMABIO, will pursue a number of rare, large indications.  A new spinout, RareTx, will be dedicated to Orphan…

Continue Reading Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 2

Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

The U.S. Food and Drug Administration has approved UCB's Kygevvi, marking a historic milestone for patients with thymidine kinase 2 deficiency (TK2d), an ultra-rare inherited mitochondrial disorder that has lacked…

Continue Reading Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

Soleno Therapeutics Achieves Historic Q3 Milestone: VYKAT XR Drives Company to First Profitable Quarter

Soleno Therapeutics marked a significant turning point in its corporate history by reporting its first profitable quarter, driven by robust sales of VYKAT XR, its groundbreaking therapy for Prader-Willi Syndrome…

Continue Reading Soleno Therapeutics Achieves Historic Q3 Milestone: VYKAT XR Drives Company to First Profitable Quarter